

Resource Summary Report

Generated by [RRID](#) on Aug 9, 2026

CD56-VioBright 515, human

RRID:AB_2658743

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-109-046, RRID:AB_2658743

Antibody Information

URL: http://antibodyregistry.org/AB_2658743

Proper Citation: Miltenyi Biotec Cat# 130-109-046, RRID:AB_2658743

Target Antigen: CD56

Host Organism: human

Clonality: monoclonal

Comments: Discontinued: 6-2018; Target Distribution NK cells, T cells; target type CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity: Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-114-743. (RRID:AB_2726781).

Antibody Name: CD56-VioBright 515, human

Description: This monoclonal targets CD56

Target Organism: non-human primate, human

Clone ID: REA196

Antibody ID: AB_2658743

Vendor: Miltenyi Biotec

Catalog Number: 130-109-046

Record Creation Time: 20250819T204637+0000

Record Last Update: 20250819T204702+0000

Ratings and Alerts

No rating or validation information has been found for CD56-VioBright 515, human.

Warning: Discontinued: 2021

Discontinued: 6-2018; Target Distribution NK cells, T cells; target type CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-114-743. (RRID:AB_2726781).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Chen Y, et al. (2025) A Machine Learning-Based Strategy Predicts Selective and Synergistic Drug Combinations for Relapsed Acute Myeloid Leukemia. Cancer research, 85(14), 2753.